Literature DB >> 8489493

Is complex II involved in the inhibition of mitochondrial respiration by N-methyl-4-phenylpyridinium cation (MMP+) and N-methyl-beta-carbolines?

M J Krueger1, A K Tan, B A Ackrell, T P Singer.   

Abstract

It has been reported that N-methyl-beta-carbolinium analogues of the neurotoxic N-methyl-4-phenylpyridinium cation (MPP+) inhibit NADH-linked mitochondrial oxidations, as well as mitochondrial respiration on succinate nearly to the same extent [Fields, Albores, Neafsey and Collins (1992) Arch. Biochem. Biophys. 294, 539-544]. Those authors further claimed that MPP+ itself also blocks respiration through succinate dehydrogenase, in addition to its well-known effect on NADH dehydrogenase (Complex I), and concluded that both effects may contribute to the development of Parkinsonian symptoms. Since N-methyl-beta-carboliniums are thought to be endogenous metabolites, these findings, if verified, would have important implications on the etiology of idiopathic Parkinsonism. We have re-examined these observations, using mitochondria after full activation of succinate dehydrogenase, as well as submitochondrial particles, in which complexities due to membrane transport are not present. We report the following observations. (1) N-Methyl-beta-carboliniums inhibit mitochondrial respiration on NAD(+)-linked substrates in a time-dependent manner, and the inhibition is potentiated by the presence of tetraphenylboron anion (TPB-), as expected for positively charged compounds. (2) Unlike MPP+ itself, however, these compounds are uncouplers at higher concentrations, so that the effects seen in State 3 cannot be assigned exclusively to inhibition of NADH oxidation. (3) The effects on succinate oxidation in mitochondria, in which the full activity of the enzyme is expressed, are 1-1.5 orders of magnitude lower than on respiration via Complex I and are thus unlikely to contribute significantly to the neurotoxicity. (4) The effect of MPP+ on mitochondrial respiration via succinate dehydrogenase is trivial, in accord with previous reports from several laboratories, but contradicting the findings of Fields et al. (cited above). (5) In submitochondrial particles the inhibition of NADH oxidation (via the complete respiratory chain) has been confirmed, but it differs markedly from the action of MPP+ in two respects. First, the enhancement by TPB- is very small; secondly, the inhibition of NADH oxidation measured using ubiquinone (Q) analogues is far lower, suggesting that Complex I is not the only target. (6) In submitochondrial particles the inhibition of succinate oxidation by either O2 or Q analogues is incomplete, trivial or absent. (7) We thus conclude that we find no basis for assigning any potential biological effect of N-methyl-beta-carboliniums to the blockade of succinate oxidation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8489493      PMCID: PMC1132419          DOI: 10.1042/bj2910673

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  10 in total

1.  The inhibition site of MPP+, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is near the Q-binding site of NADH dehydrogenase.

Authors:  R R Ramsay; A T Kowal; M K Johnson; J I Salach; T P Singer
Journal:  Arch Biochem Biophys       Date:  1987-12       Impact factor: 4.013

2.  Enhancement by tetraphenylboron of the interaction of the 1-methyl-4-phenylpyridinium ion (MPP+) with mitochondria.

Authors:  R R Ramsay; R J Mehlhorn; T P Singer
Journal:  Biochem Biophys Res Commun       Date:  1989-03-31       Impact factor: 3.575

3.  Determination of the activity of succinate, NADH, choline, and alpha-glycerophosphate dehydrogenases.

Authors:  T P Singer
Journal:  Methods Biochem Anal       Date:  1974

4.  Mitochondrial respiratory inhibition by N-methylated beta-carboline derivatives structurally resembling N-methyl-4-phenylpyridine.

Authors:  R Albores; E J Neafsey; G Drucker; J Z Fields; M A Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

5.  Structural dependence of the inhibition of mitochondrial respiration and of NADH oxidase by 1-methyl-4-phenylpyridinium (MPP+) analogs and their energized accumulation by mitochondria.

Authors:  R R Ramsay; S K Youngster; W J Nicklas; K A McKeown; Y Z Jin; R E Heikkila; T P Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

6.  Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+.

Authors:  R R Ramsay; J I Salach; T P Singer
Journal:  Biochem Biophys Res Commun       Date:  1986-01-29       Impact factor: 3.575

7.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

Authors:  W J Nicklas; I Vyas; R E Heikkila
Journal:  Life Sci       Date:  1985-07-01       Impact factor: 5.037

8.  Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium.

Authors:  I Vyas; R E Heikkila; W J Nicklas
Journal:  J Neurochem       Date:  1986-05       Impact factor: 5.372

9.  Potentiation by the tetraphenylboron anion of the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its pyridinium metabolite.

Authors:  R E Heikkila; J Hwang; S Ofori; H M Geller; W J Nicklas
Journal:  J Neurochem       Date:  1990-03       Impact factor: 5.372

10.  Inhibition of mitochondrial succinate oxidation--similarities and differences between N-methylated beta-carbolines and MPP+.

Authors:  J Z Fields; R R Albores; E J Neafsey; M A Collins
Journal:  Arch Biochem Biophys       Date:  1992-05-01       Impact factor: 4.013

  10 in total
  3 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 2.  Mitochondrial dysfunction in neurodegeneration.

Authors:  J M Cooper; A H Schapira
Journal:  J Bioenerg Biomembr       Date:  1997-04       Impact factor: 2.945

Review 3.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.